IMMX — Immix Biopharma Income Statement
0.000.00%
Last trade - 00:00
- $54.94m
- $25.34m
- 31
- 21
- 27
- 16
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 0.843 | 0.454 | 1.44 | 8.22 | 16.1 |
Operating Profit | -0.843 | -0.454 | -1.44 | -8.22 | -16.1 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -0.952 | -1.13 | -24.4 | -8.22 | -15.6 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.973 | -1.15 | -24.4 | -8.23 | -15.6 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -0.973 | -1.15 | -24.4 | -8.23 | -15.4 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.973 | -1.15 | -24.4 | -8.23 | -15.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.135 | -0.159 | -3.38 | -0.593 | -0.89 |